Expression of Cyclooxygenase-1 and -2 in Normal and Glaucomatous Human Eyes


PURPOSE. Primary open-angle glaucoma (POAG) is the predominant form of chronic glaucoma, but the underlying pathologic mechanisms are largely unknown. Because prostaglandins (PGs) have been introduced into POAG treatment with remarkable success, this study was undertaken to investigate whether a change in the expression of the PG-synthesizing enzymes cyclooxygenase (COX)-1 and -2 might be involved in the pathogenesis of POAG.

METHODS. Expression of COX-1 and -2 was assessed by confocal laser microscopy, immunohistochemistry, Western blot analysis, and real-time RT-PCR in human eyes with different forms of glaucoma (primary open-angle, angle-closure, congenital juvenile, and steroid-induced), as well as in age-matched control eyes. Additionally, PGE2 was measured in aqueous humor by means of an enzyme-linked immunoassay as a product of COX activity.

RESULTS. In normal eyes, ocular COX-1 and -2 expression were largely confined to the nonpigmented secretory epithelium of the ciliary body. By immunohistochemistry and real-time RT-PCR, COX-2 expression was completely lost in the nonpigmented secretory epithelium of the ciliary body of eyes with end-stage POAG, whereas COX-1 expression was unchanged. By immunohistochemistry, in the ciliary bodies of eyes in five patients with diagnosis of early POAG, eyes in two had complete loss of COX-2 expression and in three showed only a few remaining scattered COX-2-expressing cells. COX-2 expression in the ciliary body was also lost in patients with steroid-induced glaucoma and was reduced in patients receiving topical steroid treatment. Eyes of patients with either congenital juvenile or angle-closure glaucoma showed COX-2 expression indistinguishable from control eyes. Aqueous humor of eyes with POAG contained significantly less PGE2 than control eyes.

CONCLUSIONS. Both cyclooxygenase isoforms are constitutively expressed in the normal human eye. Specific loss of COX-2 expression in the nonpigmented secretory epithelium of the ciliary body appears to be linked to the occurrence of POAG and steroid-induced glaucoma.

Primary open-angle glaucoma (POAG) is among the dominating ocular diseases in industrialized countries. Intracocular pressure (IOP) increases in persons older than 50 years without any subjective symptoms until irreversible damage occurs. If untreated, it leads to impaired vision and ultimately to blindness in approximately 2% of the elderly population. The pathogenesis of POAG is still largely unknown, although in some patients there is evidence of genetic linkage to GLC1A/B.

POAG shares several characteristics with corticosteroid hormone-induced secondary open-angle glaucoma. Prolonged topical administration of glucocorticoids to the eye causes increased IOP and a decay of vision in about 30% of the patients. Glucocorticoids are well known to inhibit the expression of cyclooxygenase (COX)-2, a key enzyme in the formation of prostaglandins (PGs). These agents play an important role in the regulation of IOP. Therefore, reduction of PGs in the eye by inhibition of COX-2 expression appears to be a mechanism by which glucocorticoids cause secondary glaucoma. In fact, synthetic PGF2α analogues such as latanoprost are remarkably effective in glaucoma therapy.

PG production involves two isoenzymes, COX-1 and -2. Today, it is generally assumed that COX-1 is constitutively expressed in most tissues and displays the characteristics of a “housekeeping” enzyme. By contrast, COX-2 is the product of an immediate early gene that is rapidly inducible and tightly regulated. Under normal conditions, COX-2 expression is highly restricted to certain organs including the central nervous system (CNS) and the kidney. However, it has been shown that COX-2 expression can be dramatically increased in various tissues after initiation of transcription by activating factors including different proinflammatory cytokines, shear forces in the arterial wall, or salt deprivation.

In view of the potential importance of cyclooxygenases in glaucoma, the localization and expression of these enzymes in normal and glaucomatous human eyes was investigated.

MATERIALS AND METHODS

Informed consent to eye and tissue donation was obtained and the study adhered to the tenets of the Declaration of Helsinki.

Immunofluorescence and Confocal Laser Microscopy

Anterior segments prepared from normal human donor eyes were embedded in optimal cutting temperature compound (OCT; Tissue-Tek; Miles Laboratories, Elkhart, IN) and snap frozen in isopentane-liquid nitrogen. Six-micrometer cryostat sections were thawed onto gelatin-coated glass slides, air dried, and fixed in paraformaldehyde (4%, 10 minutes) followed by incubation in Tris-buffered saline (TBS; pH 7.4) containing 10% normal donkey serum and 1% bovine serum

Copyright © Association for Research in Vision and Ophthalmology
albumin (BSA) for 60 minutes at room temperature (RT). After the slides were rinsed in TBS, incubation was continued with the polyclonal goat anti-human COX-1 or -2 antisera (dilution, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) in TBS containing 1% BSA overnight at 4°C. After slides were again rinsed with TBS, binding sites were detected using donkey anti-goat IgG conjugated with cyanine-3 (diluted 1:200 in TBS, for 1 hour at RT; Santa Cruz Biotechnology). Sections were counterstained with TBS-glycerol (1:1, pH 8.6) and examined by confocal laser scanning microscopy (MRC 1000; Bio-Rad, Richmond, CA).

**Expression of COX-1 and COX-2**

To investigate COX-2 mRNA expression in glaucomatous eyes, total-RNA was isolated from paraffin-embedded eye sections fixed with 4% formaldehyde (fixation time, <12 hours). Ten-micrometer-thick slices of respective eyes were cut. Afterward, ciliary processes were separated by means of microdissection and transferred into cups (Eppendorf, Fremont, CA). All isolation steps were performed at room temperature in the same cup. First, paraffin was dissolved in Roticlear (Carl Roth GmbH, Karlsruhe, Germany). The solution was then centrifuged at full speed for 5 minutes, and the supernatant was removed. This procedure was followed by three intensive washing steps with ethanol (96%) to remove the Roticlear agent. After the last wash, ethanol was totally removed and the pellet was air dried. All steps were performed in detail, according to the manufacturer’s protocol (Mini RNAeasy; Qiagen) Protocol. After adding 350 μl of lysis buffer, the tissue samples were stored with a microshredder.

For RT-PCR, 1 μg tissue RNA was reverse transcribed into cDNA (Superscript II Polymerase; Life Technologies GmbH, Eggstein, Germany). Special primers were designed for the detection of potential fragmented RNA, according to reports in the respective literature. In particular, they should amplify very short target sequences. The sequences of the oligonucleotide primers (Eurogentec, Liege, Belgium) were COX-1 (79 bp): 5’-CACAATTCGGCT-GAGGGCAAC-3’ (upstream), and 5’-ACTGGTTATTTCTCCTGTCGTC-3’ (downstream), and 5’-(FAM)CCTGCGACAGCA (TAMRA)TTTCGGCTG-5’-GTGAAT-3’ (internal oligonucleotide probe); COX-2 (88 bp): 5’-GCTGGAACAATGCAACTCCAAC-3’ (upstream), 5’-TTGCTGATACTGCGGTGAAT-3’ (downstream), and 5’-(FAM)CTGCCACAGACA (TAMRA)TTTGGCTGGAAT-3’ (internal oligonucleotide probe); and β-actin (79 bp): 5’-AGTACGCGGTGCACTGATC-3’ (upstream), 5’-GCTGATACTGCGGTGAAT-3’ (downstream), and 5’-(FAM)CTGCCACAGAC (TAMRA)TTTGGCTGGAAT-3’ (internal oligonucleotide probe). mRNAs were determined using a real-time thermal cycler (ABI 7700; Perkin Elmer-Applied Biosystems) using a kit (AmpliTaq Gold; Perkin Elmer-Applied Biosystems).

**Light Microscopic Immunohistochemistry**

Immunohistochemistry was performed on paraffin-embedded eye sections from the archives of the Department of Ophthalmology of the University of Erlangen-Nürnberg and on donor eyes from the Glaucoma Research Foundation (San Francisco, CA), both fixed with 4% formaldehyde. The labeled streptavidin-biotin method performed with a kit (LSAB Plus; Dako, Glostrup, Denmark) was applied according to the manufacturer’s instructions. Briefly, after endogenous peroxidase activity of the tissue was quenched with 3% hydrogen peroxide in distilled water for 5 minutes, sections were incubated with proteinase K (0.02 mg/ml in TBS; pH 8) for 20 minutes for antigen unmasking. After sections were rinsed, they were incubated with a polyclonal goat anti-human COX-1 or -2 antibody (dilution, 1:1000; Santa Cruz, CA) in TBS containing 1% BSA overnight at 4°C. After slides were again rinsed with TBS, binding sites were detected using donkey anti-goat IgG conjugated with cyanine-3 (diluted 1:200 in TBS, for 1 hour at RT; Santa Cruz Biotechnology). Sections were counterstained with TBS-glycerol (1:1, pH 8.6) and examined by confocal laser scanning microscopy (MRC 1000; Bio-Rad, Richmond, CA).

**Light Microscopic Immunohistochemistry**

Immunohistochemistry was performed on paraffin-embedded eye sections from the archives of the Department of Ophthalmology of the University of Erlangen-Nürnberg and on donor eyes from the Glaucoma Research Foundation (San Francisco, CA), both fixed with 4% formaldehyde. The labeled streptavidin-biotin method performed with a kit (LSAB Plus; Dako, Glostrup, Denmark) was applied according to the manufacturer’s instructions. Briefly, after endogenous peroxidase activity of the tissue was quenched with 3% hydrogen peroxide in distilled water for 5 minutes, sections were incubated with proteinase K (0.02 mg/ml in TBS; pH 8) for 20 minutes for antigen unmasking. After sections were rinsed, they were incubated with a polyclonal goat anti-human COX-1 or -2 antibody (dilution, 1:1000; TBS), incubation was continued with the polyclonal goat anti-human COX-1 or -2 antisera (dilution, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) in TBS containing 1% BSA overnight at 4°C. After slides were again rinsed with TBS, binding sites were detected using donkey anti-goat IgG conjugated with cyanine-3 (diluted 1:200 in TBS, for 1 hour at RT; Santa Cruz Biotechnology). Sections were counterstained with TBS-glycerol (1:1, pH 8.6) and examined by confocal laser scanning microscopy (MRC 1000; Bio-Rad, Richmond, CA).

**Expression of COX-1 and COX-2**

To investigate COX-2 mRNA expression in glaucomatous eyes, total-RNA was isolated from paraffin-embedded eye sections fixed with 4% formaldehyde (fixation time, <12 hours). Ten-micrometer-thick slices of respective eyes were cut. Afterward, ciliary processes were separated by means of microdissection and transferred into cups (Eppendorf, Fremont, CA). All isolation steps were performed at room temperature in the same cup. First, paraffin was dissolved in Roticlear (Carl Roth GmbH, Karlsruhe, Germany). The solution was then centrifuged at full speed for 5 minutes, and the supernatant was removed. This procedure was followed by three intensive washing steps with ethanol (96%) to remove the Roticlear agent. After the last wash, ethanol was totally removed and the pellet was air dried. All steps were performed in detail, according to the manufacturer’s protocol (Mini RNAeasy; Qiagen) Protocol. After adding 350 μl of lysis buffer, the tissue samples were stored with a microshredder.

For RT-PCR, 1 μg tissue RNA was reverse transcribed into cDNA (Superscript II Polymerase; Life Technologies GmbH, Eggstein, Germany). Special primers were designed for the detection of potential fragmented RNA, according to reports in the respective literature. In particular, they should amplify very short target sequences. The sequences of the oligonucleotide primers (Eurogentec, Liege, Belgium) were COX-1 (79 bp): 5’-CACAATTCGGCTA CAATCCA (upstream), and 5’-ACTGGTTATTTCTCCTGTCG TC-3’ (downstream), and 5’-(FAM)CCTGCGACAGCA (TAMRA)TTTCGGCTG-5’-GTGAAT-3’ (internal oligonucleotide probe); COX-2 (88 bp): 5’-GCTGGAACAATGCAACTCCAAC-3’ (upstream), 5’-TTGCTGATACTGCGGTGAAT-3’ (downstream), and 5’-(FAM)CTGCCACAGAC (TAMRA)TTTGGCTGGAAT-3’ (internal oligonucleotide probe); and β-actin (79 bp): 5’-AGTACGCGGTGCACTGATC-3’ (upstream), 5’-GCTGATACTGCGGTGAAT-3’ (downstream), and 5’-(FAM)CTGCCACAGAC (TAMRA)TTTGGCTGGAAT-3’ (internal oligonucleotide probe). mRNAs were determined using a real-time thermal cycler (ABI 7700; Perkin Elmer-Applied Biosystems) using a kit (AmpliTaq Gold; Perkin Elmer-Applied Biosystems).

**Light Microscopic Immunohistochemistry**

Immunohistochemistry was performed on paraffin-embedded eye sections from the archives of the Department of Ophthalmology of the University of Erlangen-Nürnberg and on donor eyes from the Glaucoma Research Foundation (San Francisco, CA), both fixed with 4% formaldehyde. The labeled streptavidin-biotin method performed with a kit (LSAB Plus; Dako, Glostrup, Denmark) was applied according to the manufacturer’s instructions. Briefly, after endogenous peroxidase activity of the tissue was quenched with 3% hydrogen peroxide in distilled water for 5 minutes, sections were incubated with proteinase K (0.02 mg/ml in TBS; pH 8) for 20 minutes for antigen unmasking. After sections were rinsed, they were incubated with a polyclonal goat anti-human COX-1 or -2 antibody (dilution, 1:1000 in TBS), incubation was continued with the polyclonal goat anti-human COX-1 or -2 antisera (dilution, 1:1000; Santa Cruz, CA) in TBS containing 1% BSA overnight at 4°C. After slides were again rinsed with TBS, binding sites were detected using donkey anti-goat IgG conjugated with cyanine-3 (diluted 1:200 in TBS, for 1 hour at RT; Santa Cruz Biotechnology). Sections were counterstained with TBS-glycerol (1:1, pH 8.6) and examined by confocal laser scanning microscopy (MRC 1000; Bio-Rad, Richmond, CA).
of negative control tissues (muscle). Positive tissue controls included sections of brain, kidney, and uterus (data not shown).

**Measurements of PGE₂ in Aqueous Humor**

Aqueous humor obtained at eye surgery was immediately snap frozen in liquid nitrogen. PGE₂ concentrations were determined using a commercially available enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, MI). The reliable limit of quantification for PGE₂ was 15 pg/ml, and the coefficient of variation was less than 14% within the calibration range (15–1000 pg/ml).

**RESULTS**

**Expression of COX-1 and -2 in Normal Human Eyes**

The expression of COX-1 and -2 at different sites in the human eye was investigated with immunofluorescence and confocal laser microscopy (Fig. 1). In eight apparently normal eyes of human organ donors (no known ocular diseases; age range, 38–85 years), which were enucleated shortly after death (<8 hours) COX-1 and -2 IR were most prominent in the cells of the nonpigmented epithelial layer of the ciliary body (Figs. 1A, 1B, 1E). By contrast, only minor expression of both cyclooxygenases was observed in other areas of the anterior eye segments. Some COX-2 IR was observed in connective tissue cells scattered in the iris stroma (Fig. 1C), particularly in the pupillary and iris root area, as well as in some stromal cells between the ciliary muscle and the anterior chamber (Fig. 1D).

The ultrastructural localization of COX-2 was revealed by immunoelectron microscopy. The strongest staining was found in the basolateral membranes of the nonpigmented secretory epithelial cells (Fig. 2A), which secret the eye’s aqueous humor. Additionally, COX-2 protein was found in association with intercellular contacts (maculae and zonulae adherentia, Figs. 2B, 2C), and in the rough endoplasmic reticulum including the perinuclear cistern (Fig. 2D). By contrast, no COX-2 IR was detected in the pigmented epithelial layer of the ciliary body. A schematic overview of the distribution of COX-2 in the ciliary epithelium based on immunoelectron microscopy is shown in Figure 2E.

Constitutive expression of COX-2 protein was further confirmed by Western blot analysis using protein extracts from human ciliary body tissue. The antibody raised against human COX-2 protein detected a double band of approximately 68 to 75 kDa, corresponding to the molecular weight of COX-2 (Fig. 3). The detected bands were also in the same range as a parallel-run positive control.

**Expression of COX-1 and -2 in Glaucomatous Eyes**

Paraffin-embedded sections of surgically enucleated blind and painful glaucomatous eyes were obtained from the archives of the Department of Ophthalmology at the University of Erlangen, Germany. Five eyes with absolute (end-stage) POAG (72 ± 6 years), five with secondary angle-closure glaucoma due to rubeosis iridis (78 ± 7 years), and three with congenital juve-
nile glaucoma (44 ± 2 years) were analyzed. In the end-stage POAG eyes, COX-2 expression was completely lost in the nonpigmented epithelium of the ciliary body (Figs. 4C, 4D). This loss was very specific in two respects. First, loss of COX-2 expression was restricted to the nonpigmented ciliary epithelium and did not affect COX-2 expression in the connective tissue cells of the ciliary body and iris stroma (4D, inset). Second, COX-1 expression remained unchanged, both in the ciliary body and in other sites of ocular COX-1 expression (Figs. 4J, 4K). By contrast, all eyes with congenital juvenile and angle-closure glaucoma exhibited an expression of COX-2 very similar to that in normal control eyes (Figs. 4F, 4G).

Equally processed and age-matched normal human eyes obtained from organ donors and eyes enucleated for small juxtapapillary malignant melanomas of the choroid not affecting anterior segment tissues served as control eyes (Figs. 4A, 4B). The latter eyes are regarded as otherwise normal and have the advantage of a very short time until fixation of the tissue can begin. Therefore, postmortem changes can be largely excluded. These eyes showed the same COX-2 expression as observed in normal human donor eyes.

Because glucocorticoids are known to inhibit COX-2 expression in various cell types, we investigated whether topical ocular steroid treatment affects the COX-2 expression in the ciliary epithelium. Four paraffin-embedded eyes were examined from patients (75 ± 12 years) who had been treated topically with glucocorticoids preceding perforation in ulcerative herpetic keratitis. COX-2 expression was almost completely absent in glucocorticoid-treated eyes (Fig. 4H). Because the analysis was performed on paraffin-embedded sections from the archives of the Department of Ophthalmology at the University of Erlangen, the specimens were not suitable for quantitative investigations, such as Western blot analysis or RT-PCR.

To investigate COX-2 expression in earlier stages of POAG, eyes were obtained from the Glaucoma Research Eye Donor Network (GREDN) of the Glaucoma Research Foundation (time from death to dissection <8 hours). Patients with clinically diagnosed glaucoma in various stages of the disease were registered in their lifetimes by the foundation. All donors agreed that at death their eyes could be immediately enucleated and committed to glaucoma research. After evaluation of the clinical data, five eyes (80.5 ± 4 years) with earlier stages of POAG were found. All patients had typical glaucomatous visual field loss; one had already undergone glaucoma filtration surgery 2 years before his death. The cup-to-disc ratio ranged between 0.7 and 0.95. In addition, we had access to two eyes with ocular hypertension without any clinical signs of glaucoma and one eye with steroid-induced glaucoma. Of the five eyes of patients with POAG, two were completely devoid of COX-2 IR, and three still showed a few scattered COX-2-positive cells in the ciliary epithelium (Fig. 4E). COX-2-protein

Figure 3. Western blot analysis demonstrating the expression of COX-2 protein in the ciliary body of normal human donor eyes. Lane 1: Total cell lysates prepared from ciliary body tissue (50 μg protein); lane 2: purified COX-1 (0.1 μg); and lane 3: purified COX-2 protein (0.1 μg) were electrophoresed, transferred onto nitrocellulose membrane, and immunostained with polyclonal antiserum against human COX-2. The antibody used was highly specific for COX-2 and did not detect COX-1. Unpurified COX-2 proteins derived from cell lysates or tissues typically produced a double or triple band in Western blot analysis at 68 to 75 kDa (lane 1). Similar results were obtained in three independent experiments.
was completely absent in the eye with steroid-induced glaucoma (Fig. 4J).

To add further proof to our histologic and biochemical findings (described later), we tried to assess the expression of COX-2 mRNA in paraffin-embedded tissue specimens. We had access to two specimens obtained during eye surgery that were

**FIGURE 4.** Light micrographs of immunohistochemistry for COX-2 protein on paraffin-embedded eye sections. Positive cells show reddish-brown staining (in contrast to the black melanin pigment of the pigmented epithelial layer of the ciliary body). (A) Control eye enucleated for a small juxtapapillary malignant melanoma of the choroid not affecting anterior segment tissues. (B) Higher magnification of section in (A) shows intense staining of the nonpigmented epithelial layer of the ciliary body (arrow). COX-2–positive cells were also found in the connective tissue between the ciliary body and the posterior chamber (inset). The staining pattern exactly corresponded to the distribution of COX-2 IR in Figures 1A, 1B, and 1C. (C) Ciliary body of an eye with absolute POAG. (D) Higher magnification of section in (C) shows absence of COX-2 IR in the nonpigmented epithelial layer (arrow). COX-2–positive cells were still found in the connective tissue between the ciliary body and the posterior chamber (inset). Cell nuclei are stained blue. (E) Eye with an early form of POAG. IOP was elevated (24 mm Hg) and there were visual field defects. COX-2 IR was clearly reduced compared with control eyes but was still detectable in some cells of the nonpigmented ciliary epithelium (arrow). (F, G) Approximately normal content of COX-2 IR in ciliary epithelia of eyes with congenital juvenile (F) and secondary angle-closure (G) glaucoma. (H) Ciliary body of an eye pretreated with glucocorticoids showed markedly decreased content of COX-2 protein (arrow) compared with the control in (A). (I) Eye with steroid-induced glaucoma (IOP, 25 mm Hg). COX-2 IR was completely absent in this eye. (J) Section of control eye shown in (A) and (B) stained for COX-1 protein showed intense staining of the nonpigmented epithelial layer of the ciliary body (arrow). (K) Eye with absolute POAG shown in (C) and (D) stained for COX-1 protein. In sharp contrast to COX-2 IR, no change in COX-1 IR was detected (arrow) compared with the control eye (I). npe, nonpigmented epithelial layer; pe, pigmented epithelial layer. Original magnification, (A, C, F–H) ×55; (B, D, E, J, K) ×140; (B, D, inset) ×200; (I) ×150.
carefully prepared with the intention of using them for the analysis of mRNA expression. As far as possible, the specimens were processed in RNase-free conditions after enucleation of the eye. Because the specimens were fixed in paraformaldehyde and degradation of RNA could be expected, we designed special primers for the detection of small fragments (COX-1, 79 bp; COX-2, 88 bp; \(\beta\)-actin, 67 bp), according to reports in the literature.\(^{21,22}\) The fragments were supposed to be within the approximately 200 nucleotide fragments resulting from fixation. One eye with absolute (end-stage) POAG (from an 80-year-old woman) was compared with an eye enucleated due to a small juxtapapillary malignant melanoma (from a 70-year-old man), which served as a control. The respective ciliary processes were separated by microdissection, and afterward, RNA-extraction was performed. As seen in Figure 5B, the control eye showed a clear expression of COX-2 mRNA. In contrast, no COX-2 mRNA was detectable in the eye enucleated due to absolute POAG. No difference in \(\beta\)-actin and COX-1 content was observed between both eyes (Fig. 5A).

**PGE\(_2\) Concentrations in Aqueous Humor**

PGE\(_2\) content was analyzed in the ocular aqueous humor in patients with different ocular diseases (Fig. 6). PGE\(_2\) concentrations were significantly less in patients with POAG (34.3 ± 17.6 ng/ml [SEM]; \(n = 19\)) than in control patients (48.9 ± 7.6 ng/ml; \(n = 13\)) who underwent eye surgery for cataract (\(P < 0.02\); ANOVA followed by the Bonferroni post hoc test), but comparable with patients who received topical steroids (25.5 ± 2.5 ng/ml; \(n = 3\)) for treatment of anterior uveitis or
pretreated with glucocorticoids were significantly lower than in the ocular aqueous humor of eyes of patients with POAG or of patients with angle-closure glaucoma that had long-standing elevations of IOP, in that COX-2 was reduced at earlier stages of POAG development (compare Fig. 4E). Two of five eyes with early stages of POAG showed complete COX-2 loss, and three of five eyes showed COX-2 IR only in some scattered cells. Therefore, the selective loss of ciliary COX-2 expression appears to be associated with POAG and is not a consequence of increased IOP, in that COX-2 was present in normal amounts in eyes with congenital juvenile and angle-closure glaucoma that had long-standing elevations of IOP. Furthermore, COX-2 expression was already clearly reduced at earlier stages of POAG development (compare Fig. 4E). Two of five eyes with early stages of POAG showed complete COX-2 loss, and three of five eyes showed COX-2 IR only in some scattered cells. Therefore, the selective loss of ciliary COX-2 expression appears to be linked to the occurrence of POAG. Although the results obtained from our specimens were very consistent, further investigations are needed to elucidate whether reduced COX-2 expression is a common characteristic of POAG or occurs only in a particular subtype of this disease.

In addition, this study showed that COX-2 expression in the ciliary epithelium was lost in steroid-induced glaucoma and was reduced in patients treated topically with glucocorticoids. Moreover, aqueous humor of eyes treated topically with glucocorticoids contained significantly less PGE2 than did control eyes.

The proposed mechanism of corticosteroid-induced glaucoma includes morphologic and functional changes in the trabecular meshwork system. These changes are thought to be similar to those in POAG. In particular, trabecular cells of human eyes treated with glucocorticoids show endoreplication of nuclei, an increase in cell size, and excessive production of an approximately 56-kDa glycoprotein, termed trabecular meshwork glucocorticoid response protein (TIGR) and transcribed by the GLC1A gene. This may indicate that loss of COX-2 expression is secondary to changes in the trabecular meshwork system, because COX-2 expression is normal in other parts of the eye. Furthermore, the outflow resistance is markedly increased in eyes with POAG and steroid-induced glaucoma. Because PGs are known to facilitate outflow, the reduction of PGs in aqueous humor, as reported in this study, may contribute to the increased outflow resistance in POAG and steroid-induced glaucoma.

**Reduced COX-2-Expression in POAG**

This study demonstrated a complete and selective loss of COX-2 expression in the ciliary nonpigmented epithelial layer of eyes with end-stage POAG. This loss was anatomically highly selective. The changes in COX-2 expression were restricted to the secretory epithelium of the ciliary body, whereas COX-2 expression remained unchanged in other parts of the eye. COX-1 expression was unchanged throughout the eye. The loss of COX-2 expression appears to be associated with POAG and is not a consequence of increased IOP, in that COX-2 was present in normal amounts in eyes with congenital juvenile and angle-closure glaucoma that had long-standing elevations of IOP. Furthermore, COX-2 expression was already clearly reduced at earlier stages of POAG development (compare Fig. 4E). Two of five eyes with early stages of POAG showed complete COX-2 loss, and three of five eyes showed COX-2 IR only in some scattered cells. Therefore, the selective loss of ciliary COX-2 expression appears to be linked to the occurrence of POAG. Although the results obtained from our specimens were very consistent, further investigations are needed to elucidate whether reduced COX-2 expression is a common characteristic of POAG or occurs only in a particular subtype of this disease.

In addition, this study showed that COX-2 expression in the ciliary epithelium was lost in steroid-induced glaucoma and was reduced in patients treated topically with glucocorticoids. Moreover, aqueous humor of eyes treated topically with glucocorticoids contained significantly less PGE2 than did control eyes.

The proposed mechanism of corticosteroid-induced glaucoma includes morphologic and functional changes in the trabecular meshwork system. These changes are thought to be similar to those in POAG. In particular, trabecular cells of human eyes treated with glucocorticoids show endoreplication of nuclei, an increase in cell size, and excessive production of an approximately 56-kDa glycoprotein, termed trabecular meshwork glucocorticoid response protein (TIGR) and transcribed by the GLC1A gene. This may indicate that loss of COX-2 expression is secondary to changes in the trabecular meshwork system, because COX-2 expression is normal in other parts of the eye. Furthermore, the outflow resistance is markedly increased in eyes with POAG and steroid-induced glaucoma. Because PGs are known to facilitate outflow, the reduction of PGs in aqueous humor, as reported in this study, may contribute to the increased outflow resistance in POAG and steroid-induced glaucoma.

**PGE2 Concentration in the Aqueous Humor in POAG**

The PGE2 concentration in the aqueous humor of glaucomatous eyes was found to be significantly lower than in control eyes. The decrease in endogenous PGs may contribute to the elevation of IOP in the glaucomatous eyes. This is consistent with the utility of PG derivatives in the treatment of POAG. For example, PGE2 analogues have been introduced into the therapy of POAG with remarkable success.

PGE2 is thought to influence uveoscleral outflow through interaction with PGF receptors. These receptors are located in proximity to the localization of COX-1 and -2 described in this study. In addition, at least part of the effects of PGE2 occur through PGF2α-induced PGE2 release. This PG has been shown to decrease IOP, as well. It is not known which of the various PGs is the most relevant in the human eye. However, the predominant prostanooid receptor in the human ciliary body is EP3. Stimulation of this receptor seems to be more important for reduction of IOP than stimulation of the FP receptor. This is consistent with our observation that the PGE2 content of the aqueous humor in human eyes exceeded that of PGF2α, several times.

PGF2α concentrations in aqueous humor of patients with POAG showed considerable interindividual variation, although overall the data demonstrate significantly lower concentrations of PGE2 in POAG. The PG-concentration in the ocular fluid is the sum of all COX-activity in anterior eye segments. We suggest there would be a more dramatic reduction of PGE2, if PG production in the ciliary epithelium alone could be measured.

Nevertheless, our PG measurements agree with our immunohistochemical and molecular biological data and provide supportive evidence for a decreased COX-2-expression in POAG.

**Constitutive Expression of COX-1 and -2 in the Human Eye**

This is the first study that describes a constitutive expression of both COX isofoms in the anterior segments of normal human eyes. Neufeld et al. have investigated the expression of COX isofoms in the human optic nerve head of normal and glaucomatous eyes. They found no basal COX-2 expression in the optic nerve and only a slight increase of COX-2 IR in POAG. It was argued that COX-2-derived PGs might play a role in the pathogenesis of glaucomatous optic neuropathy. In the anterior segments of the eye, the ability of the ciliary epithelium and the ciliary body to produce PGs has been previously described. Yousufzai et al. reported that release of PGE2 is inhibited by dexamethasone in a dose-dependent manner.

![Figure 6](image-url)
They suggested that this inhibition may be due to inhibition of phospholipase A₂. However, inhibition of phospholipase A₂ by glucocorticoids occurs only at very high dosages.⁴⁷ An alternative and more likely mechanism is the hormonal regulation of constitutively expressed COX-2.¹²,¹⁴,¹⁶ The glucocorticoid-dependent COX-2 expression, and therefore PG production, may comprise a mechanism by which IOP is regulated under physiological conditions. Circadian oscillations of endogenous glucocorticoid plasma levels may well contribute to the circadian rhythm of IOP.

In addition, ocular COX-2 expression appears to be regulated by glucocorticoids. Our findings further extend the concept¹⁴ that COX-2 contributes constitutively to the physiological regulation in highly differentiated organ systems such as the central nervous system (CNS),¹⁵,¹⁶ the kidney,¹⁷ and, now, the eye. One explanation for this finding may be that the eye ontogenetically originates from the neuroepithelium and shares many characteristics with the CNS.

It is at present not known what factors lead to the observed decrease in COX-2 expression in POAG. These patients are not generally without COX-2, for the absence of expression is confined to the ciliary epithelium of the eye (e.g., stromal cells in the ciliary body and iris of eyes with POAG exhibit normal COX-2 IR). This specific loss may be explained either by the existence of COX-2 inducers specific for the ciliary body or by a failure within the ciliary epithelium. It is interesting to note that the TIGR gene, in which several gene mutations have been reported in familial forms of POAG,¹⁸ is located in close proximity to the human COX-2 gene. The TIGR gene has been mapped to chromosomal region 1q24.3-q25.2.¹⁹ Tay et al.¹⁹ assigned the human COX-2 gene to 1q25. Furthermore, promoters of both genes have glucocorticoid response elements. Thus, the COX-2 and TIGR genes share similarities regarding regulation of expression. Interactions of both genes and their products may be possible, although chromosomal linkage of two different genes does not necessarily imply any interactions.

The implications of decreased COX-2 expression are unknown. In particular, it remains unclear whether decreased COX-2 expression contributes to the increased IOP in POAG or is just an epiphenomenon of the pathogenesis of POAG. Unlike most other organ systems, the eye has no PG-metabolizing enzymes. PGs are removed from the aqueous humor by a glaucomatous outflow.⁵²–⁵⁴ These enzymes are known to degrade proteins of the extracellular matrix and thereby facilitate uveoscleral or trabecular meshwork outflow.⁵²–⁵⁴ This mode of PG action is thought to contribute to the IOP-decreasing effect of PGs. Lower levels of PGs in aqueous humor as reported in this study may then give rise over time to an increased outflow resistance.

In summary, this study reports for the first time that both COX isoforms are constitutively expressed in anterior segments of normal human eyes. Unlike in congenital juvenile or angle-closure glaucoma, COX-2 expression was strongly reduced or abolished in the ciliary epithelium of eyes with POAG and steroid-induced glaucoma. This study may provide new insights in the pathogenesis of POAG. The functional implications of reduced COX-2 expression will be the subject of future investigations.

Acknowledgments

The authors thank Ivan Otterness, visiting professor of the Department of Pharmacology, University of Erlangen, for helpful suggestions and corrections; Carmen Rummelt and Elke Meyer (Department of Ophthalmology), Antonia Kellenberger (Department of Anatomy) and Beale Layh and Isadella Kolberg (Department of Pharmacology, University of Erlangen) for excellent technical support during immunohistochemical procedures; Justine Borger for keeping up with the artwork; and Winfried Neuhuber (Department of Anatomy, University of Erlangen) for experimental support regarding confocal laser scanning microscopy.

References


